Anxiety Disorders

What is new in research on transcranial magnetic stimulation?

From TMS as a treatment for long COVID to an update on 988 and crisis care, here are highlights from the week in Psychiatric Times.

Fasedienol meets trial endpoints by reducing anxiety during public speaking simulations in patients with social anxiety disorder.

Black mothers in the US experience far worse outcomes. Here’s what clinicians need to know.

This book asks us to reexamine anxiety…

Here’s everything you need to know to about how to integrate apps into your clinical practice.

From research updates on at-home ketamine use to the effects of comorbid depression and anxiety on insomnia treatment, here are highlights from the week in Psychiatric Times.

New research finds depressive and anxiety symptoms impact effectiveness of cognitive behavioral therapy for insomnia.

1 in 5 respondents reported using psychedelic drugs for the purpose of self-treating anxiety, depression, or other mental illnesses.

PME affects many women, yet it remains under-recognized in clinical practice and in research.

Metabolic mediators of anxious depression? Researchers investigated metabolic correlates of overweight/obesity in patients with MDD.

Researchers used an observational cohort study to investigate a potential causal association.

Ketamine is relatively new to the average American. What can you share with them as a mental health clinician?

Ulotaront, a trace amine-associated receptor 1 agonist with 5-HT1A agonist activity, is under investigation for the treatment of generalized anxiety disorder.

From to co-occurring substance use and eating disorders to treatment options for OCD, here are highlights from the week in Psychiatric Times.

Here’s why TMS is a treatment option to consider in obsessive-compulsive disorder.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.

Screening for the symptom of worthlessness could save your adolescent patient’s life…

The experts weighed in on a wide variety of psychiatric issues for the October 2022 issue of Psychiatric Times.

"Among adults living in the United States, 38% to 40% use complementary and alternative medicine therapies, yet only 42% have told their primary physician that they do so."

At-home ketamine treatment initiated by an online provider presents many legal, clinical, and ethical challenges...

From historic USPSTF draft screening recommendations to the need for novel treatments for bipolar depression, here are highlights from the week in Psychiatric Times.

How can we increase assessment of anxiety without increasing other problems? Where is the balance?

For the first time, the USPSTF is recommending anxiety screening for adults under 65.

The first patient has been dosed in the phase 2b dose-optimization trial of a pharmaceutically optimized form of LSD for the treatment of generalized anxiety disorder.